Form 4: ORAGENICS Director Sells Shares, Receives Options

ORAGENICS Director Fred Telling reported the sale of 210 common shares and the grant of 125,000 stock options under the company's incentive plan.

Summary

• Director Fred Telling, a 10% owner of ORAGENICS INC (OGEN), reported transactions on December 11 and 12, 2025.
• On December 12, 2025, Telling sold 210 shares of common stock at a weighted average price of $0.9446 per share, with individual transactions ranging from $0.9440 to $0.9451.
• Following this sale, Telling beneficially owns 34,538 shares of common stock directly.
• On December 11, 2025, Telling was awarded 125,000 non-employee director options to purchase common stock.
• These options have an exercise price of $0.93 per share, vest immediately, and expire on December 11, 2035.
• The options were granted under the Company's 2021 Equity Incentive Plan as part of the non-employee director compensation program.

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction involving both a small sale and a significant option grant. The small sale is offset by the larger option award, resulting in a neutral overall sentiment as it's a standard compensation and disclosure event.

Positives

• Grant of 125,000 stock options to a director, indicating continued alignment of management interests with shareholder value.
• Options vest immediately, providing immediate equity exposure.

Negatives

• A director sold 210 shares of common stock, although this is a very small amount relative to the option grant.

Future Outlook

NA

Industry Context

This Form 4 filing details routine insider transactions for a director of ORAGENICS INC, a biotechnology company. Such filings are standard disclosures and do not inherently reflect broader industry trends, though they provide transparency into insider holdings and compensation practices.

Stakeholder Impact

• Shareholders: Minimal direct impact due to the small number of shares sold. The option grant aligns director interests with long-term share price appreciation.
• Employees, Customers, Suppliers, Creditors: No direct impact from this specific filing.

Key Dates

Keywords

ORAGENICS INC, OGEN, Fred Telling, Director, Insider Trading, Stock Options, Equity Incentive Plan, Common Stock Sale, SEC Form 4